Table 1.
Parameter | Total (%) | Symptomatic a N (%) | p-value |
---|---|---|---|
No of patients |
100 (100) |
59 (59) |
|
Gender |
|
|
0.65 |
Male/Female |
60(60)/40(40) |
35(58.3)/26(65) |
|
Age |
|
|
0.011 |
Symptomatic (IQR) |
|
59.5-73 yrs |
|
Asymptomatic (IQR) |
54-66 yrs |
||
Stageb |
|
|
0.36 |
I |
6 (6) |
1 (16.7) |
|
II |
5 (5) |
4 (80) |
|
III |
78 (78) |
48 (61.5) |
|
IV |
11 (11) |
6 (54.5) |
|
Tumor locationb |
|
|
0.97 |
LLL |
15 (15) |
10 (66.7) |
|
LUL |
25 (25) |
15 (60) |
|
RLL |
9 (9) |
6 (66.7) |
|
RML |
6 (6) |
4 (66.7) |
|
RUL |
45 (45) |
24 (53.3) |
|
Tumor histologyb |
|
|
0.66 |
Adenocarcinoma |
57 (57) |
30 (52.6) |
|
Neuroendocrine |
1 (1) |
1 (100) |
|
Non-small |
18 (18) |
13 (72.2) |
|
Squamous |
24 (24) |
15 (62.5) |
|
Treatment typeb |
|
|
0.89 |
IMRT |
64 (64) |
35 (54.7) |
|
Proton |
13 (13) |
9 (69.2) |
|
3D Conformal |
23 (23) |
15 (65.2) |
|
Chemotherapy status |
|
|
0.66 |
Concurrent |
86 (86) |
52 (60.5) |
|
RT alone |
14 (14) |
7 (50) |
|
Smoking historyb |
|
|
0.92 |
Currently |
28 (28) |
15 (53.6) |
|
Former |
66 (66) |
40 (60.6) |
|
Never |
6 (6) |
4 (66.7) |
|
Interval between staging PET/CT and start of RT |
0.65 | ||
Median (range) in days | 18 (3–69) | 15 (3–69) |
aSymptomatic status: CTCAEv4 RP grade ≥ 2.
bYates’ continuity correction applied.
IQR: Inter-quartile range.
Note: Hypothesis testing for association used the Mann–Whitney U test for continuous predictors; Pearson’s chi-squared test for marginal homogeneity for categorical predictors.